The popularity of diabetes drugs now being used for treatment of obesity has exploded worldwide. It is a cash cow for Big Pharma, and the success of the obesity drugs has altered the economy of a Nordic country as well as now starting to influence the food industry. According to The Wall Street Journal, 7% of the American population will be on weight loss drug and serious projections are that this metabolic space may well be worth north of $100 billion. With those kinds of numbers of course the investment sector monitors closely. How can they cash in on the economic prospects of the new wave of interest in the obesity market. But in a country where weight loss drugs are not as readily available a new “Gray Market” has emerged.
Free access provides up to 10 articles
Subscription options start at $5 per month
which is less than a Starbucks coffee!